Laurent Chardonnet - Axcella Health Consultant
| AXLADelisted Stock | USD 0.20 0.02 11.11% |
Insider
Laurent Chardonnet is Consultant of Axcella Health
| Age | 58 |
| Phone | 857 320 2200 |
| Web | https://www.axcellahealth.com |
Axcella Health Management Efficiency
The company has return on total asset (ROA) of (0.877) % which means that it has lost $0.877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (13.7017) %, meaning that it created substantial loss on money invested by shareholders. Axcella Health's management efficiency ratios could be used to measure how well Axcella Health manages its routine affairs as well as how well it operates its assets and liabilities.Axcella Health currently holds 2.16 M in liabilities with Debt to Equity (D/E) ratio of 3.02, implying the company greatly relies on financing operations through barrowing. Axcella Health has a current ratio of 2.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axcella Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Lawrence CPA | Adial Pharmaceuticals | 68 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| David Hanley | Nuvation Bio | 54 | |
| Mark Peikin | Adial Pharmaceuticals | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
| AO FRACP | Assembly Biosciences | 65 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| MBA MBA | Adial Pharmaceuticals | 46 | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Ronald CPA | RenovoRx | N/A | |
| Peter Hecht | Cyclerion Therapeutics | 60 | |
| Stacy Markel | Nuvation Bio | 59 | |
| Thomas Templeman | Nuvation Bio | 60 | |
| Sumita JD | Instil Bio | 50 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Jessica Rennekamp | Cyclerion Therapeutics | N/A | |
| Jack Reich | Adial Pharmaceuticals | 75 | |
Management Performance
| Return On Equity | -13.7 | |||
| Return On Asset | -0.88 |
Axcella Health Leadership Team
Elected by the shareholders, the Axcella Health's board of directors comprises two types of representatives: Axcella Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axcella. The board's role is to monitor Axcella Health's management team and ensure that shareholders' interests are well served. Axcella Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axcella Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Virginia Dean, VP Officer | ||
| Dan Kirby, VP Operations | ||
| Laurent Chardonnet, Consultant | ||
| William Hinshaw, President CEO | ||
| Margaret MD, VP Officer | ||
| Paul JD, Chief VP | ||
| Alison MD, Pres Operations | ||
| Larry Bell, Global VP | ||
| Robert Crane, VP CFO |
Axcella Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axcella Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -13.7 | |||
| Return On Asset | -0.88 | |||
| Current Valuation | 1.94 M | |||
| Shares Outstanding | 2.95 M | |||
| Shares Owned By Insiders | 15.77 % | |||
| Shares Owned By Institutions | 66.67 % | |||
| Number Of Shares Shorted | 78.18 K | |||
| Price To Earning | (1.10) X | |||
| Price To Book | 8.74 X | |||
| EBITDA | (67.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Axcella Stock
If you are still planning to invest in Axcella Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axcella Health's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |